Publication

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

Scientific Reports 9(1):9046, 2019

Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH

Subjects
Therapeutic AreaMouseTargetCompoundMethod/EndpointSpeciesBody compositionBody weightAMLN ob/ob-NASH (AMLN ob/ob-MASH) mouseBioinformaticsNon-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)FXRElafibranorHistopathology scoreImage analysisImmunohistochemistryLiver biopsyLiver morphometryPPARRNA sequencingObeticholic acid

Share this page

Resource Library

Related resources
Poster
Metabolic, biochemical and histological effects of semaglutide in a CDAA-HFD-induced non-obese and biopsy-confirmed rat model of NASH with progressive fibrosis and tumor development
Poster
Prophylactic and therapeutic hepatoprotective effects of lanifibranor in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis
Publication
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Poster
Disease progression in the non-obese CDAA-HFD mouse model of advanced NASH and fibrosis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top